[go: up one dir, main page]

SV2006002172A - Uso de tinturas de cianina para el diagnostico de enfermedades asociadas con angiogenesis -p-sv-78.503/msu - Google Patents

Uso de tinturas de cianina para el diagnostico de enfermedades asociadas con angiogenesis -p-sv-78.503/msu

Info

Publication number
SV2006002172A
SV2006002172A SV2005002172A SV2005002172A SV2006002172A SV 2006002172 A SV2006002172 A SV 2006002172A SV 2005002172 A SV2005002172 A SV 2005002172A SV 2005002172 A SV2005002172 A SV 2005002172A SV 2006002172 A SV2006002172 A SV 2006002172A
Authority
SV
El Salvador
Prior art keywords
diagnosis
diseases associated
cyanine dyes
msu
angiogenesis
Prior art date
Application number
SV2005002172A
Other languages
English (en)
Inventor
Michael Schirner
Kai Licha
Peter Hauff
Christin Perlitz
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of SV2006002172A publication Critical patent/SV2006002172A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0058—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G01N33/5758—

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Eye Examination Apparatus (AREA)
  • Peptides Or Proteins (AREA)

Abstract

USO DE CONJUGADOS DE TINTURAS DE CIANINA CON COMPONENTE LIGANTE ESPECIFICO PARA ANTIOGENESIS, PREFERIBLEMENTE CON UN COMPONENTE LIGANTE ESPECIFICO, PARA EB-D FIBRONECTINA PARA EL DIAGNOSTICO DE MICROMETASTASIS Y PEQUEÑAS LESIONES PROLIFERATIVAS, EN PARTICULAR TUMORES PRIMARIOS, PRECANCEROSIS, DISPLASIA, METAPLASIA, LESIONES INFLAMATORIAS, POR EJEMPLO PSORIASIS, ARTRITIS PASORIASICA Y/O ARTRITIS REUMATOIDE LESIONES ENDOMETRIOSICAS, Y ENFERMEDADES OCULARES ASOCIADAS CON ANTIOGENESIS
SV2005002172A 2004-07-22 2005-07-21 Uso de tinturas de cianina para el diagnostico de enfermedades asociadas con angiogenesis -p-sv-78.503/msu SV2006002172A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04017375A EP1619501B1 (en) 2004-07-22 2004-07-22 Use of cyanine dyes for the diagnosis of disease associated with angiogenesis

Publications (1)

Publication Number Publication Date
SV2006002172A true SV2006002172A (es) 2006-02-15

Family

ID=34925879

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2005002172A SV2006002172A (es) 2004-07-22 2005-07-21 Uso de tinturas de cianina para el diagnostico de enfermedades asociadas con angiogenesis -p-sv-78.503/msu

Country Status (15)

Country Link
EP (3) EP1816475A1 (es)
JP (1) JP2008506747A (es)
KR (1) KR20070062973A (es)
CN (1) CN101022835A (es)
AR (1) AR050264A1 (es)
AT (1) ATE374367T1 (es)
AU (1) AU2005263638A1 (es)
CA (1) CA2573783A1 (es)
DE (1) DE602004009169D1 (es)
PA (1) PA8640201A1 (es)
PE (1) PE20060558A1 (es)
SV (1) SV2006002172A (es)
TW (1) TW200613733A (es)
UY (1) UY29029A1 (es)
WO (1) WO2006008179A2 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1679082A1 (en) * 2005-01-07 2006-07-12 Schering AG Use of cyanine dyes for the diagnosis of proliferative diseases
EP1743658A1 (en) * 2005-07-14 2007-01-17 Schering Aktiengesellschaft Optical imaging of rheumatoid arthritis
DE102007037008B4 (de) * 2007-08-06 2015-09-10 Siemens Aktiengesellschaft Diagnosesubstanz zur Anwendung in einem Verfahren zur Bestimmung der Aggressivität eines Prostatatumors
DE102007038730A1 (de) * 2007-08-16 2009-02-19 Carl Zeiss Meditec Ag Nachweis des menschlichen Vascular Endothelial Growth Factor
US9097667B2 (en) 2007-12-14 2015-08-04 Biotium, Inc. Fluorescent compounds
WO2009103312A1 (en) * 2008-02-19 2009-08-27 Ludwig-Maximilians-Universität Ezrin, serpin b5, peroxiredoxin-2 and heat shock protein beta-1 as autoantigens for psoriasis and poststreptococcal diseases
CN101518528B (zh) * 2008-02-29 2014-02-26 史春梦 一组碳花青染料类的近红外荧光化合物的用途
WO2010091234A2 (en) 2009-02-06 2010-08-12 The General Hospital Corporation Methods of treating vascular lesions
SG177583A1 (en) * 2009-07-09 2012-02-28 Hoffmann La Roche In vivo tumor vasculature imaging
US8658434B2 (en) 2009-10-28 2014-02-25 Biotium, Inc. Fluorescent pyrene compounds
GB0922014D0 (en) 2009-12-17 2010-02-03 Ge Healthcare Ltd Novel integrin binders
WO2014122228A1 (en) 2013-02-07 2014-08-14 Westfaelische Wilhelms-Universitaet Muenster Labelled compounds that bind to alpha-v-beta-3 integrin
JP6752582B2 (ja) * 2016-02-08 2020-09-09 キヤノン株式会社 光音響イメージング用造影剤
TWI617281B (zh) * 2017-01-12 2018-03-11 財團法人工業技術研究院 傷口狀態分析方法與系統
CN108410202A (zh) * 2018-02-12 2018-08-17 成都驷博生物科技有限公司 一种喹啉七甲川菁染料的制备方法
CN110201189B (zh) * 2019-06-03 2021-12-07 沈阳药科大学 白蛋白结合型近红外荧光染料-马来酰亚胺共轭物
CN112994990B (zh) * 2021-05-20 2021-07-30 蚂蚁金服（杭州）网络技术有限公司 一种环路检测方法、装置、电子设备与存储介质

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1144688A (en) * 1987-03-17 1988-09-15 Dana-Farber Cancer Institute, Inc. A pharmaceutical composition comprising cyanine dye
GB9708265D0 (en) * 1997-04-24 1997-06-18 Nycomed Imaging As Contrast agents
DE19947559A1 (de) * 1999-09-24 2001-04-19 Schering Ag Antikörper-Farbstoffkonjugate gegen Zielstrukturen der Angiogenese zur intraoperativen Tumorranddarstellung
US6180086B1 (en) * 2000-01-18 2001-01-30 Mallinckrodt Inc. Hydrophilic cyanine dyes
CA2400622A1 (en) * 2000-02-24 2001-08-30 Eidgenossische Technische Hochschule Zurich Antibody specific for the ed-b domain of fibronectin, conjugates comprising said antibody, and their use for the detection and treatment of angiogenesis
WO2003055917A2 (en) * 2002-01-03 2003-07-10 Schering Aktiengesellschaft Conjugates comprising an antibody specific for the ed-b domain of fibronectin and their use for the detection and treatment of tumours
PL374386A1 (en) * 2002-03-11 2005-10-17 Philogen S.P.A. Selective targeting of tumor vasculature using antibody molecules
CA2514131A1 (en) * 2003-01-24 2004-08-05 Schering Ag Hydrophilic, thiol-reactive cyanine dyes and conjugates thereof with biomolecules for fluorescence diagnosis
JP5057994B2 (ja) * 2005-01-06 2012-10-24 ジーイー・ヘルスケア・アクスイェ・セルスカプ 光学イメージング
EP1679082A1 (en) * 2005-01-07 2006-07-12 Schering AG Use of cyanine dyes for the diagnosis of proliferative diseases

Also Published As

Publication number Publication date
CA2573783A1 (en) 2006-01-26
EP1619501B1 (en) 2007-09-26
DE602004009169D1 (de) 2007-11-08
ATE374367T1 (de) 2007-10-15
TW200613733A (en) 2006-05-01
WO2006008179A2 (en) 2006-01-26
CN101022835A (zh) 2007-08-22
EP1784226A2 (en) 2007-05-16
PE20060558A1 (es) 2006-07-26
JP2008506747A (ja) 2008-03-06
EP1619501A1 (en) 2006-01-25
AR050264A1 (es) 2006-10-11
PA8640201A1 (es) 2006-07-03
AU2005263638A1 (en) 2006-01-26
EP1816475A1 (en) 2007-08-08
WO2006008179A3 (en) 2007-01-11
KR20070062973A (ko) 2007-06-18
UY29029A1 (es) 2005-12-30

Similar Documents

Publication Publication Date Title
SV2006002172A (es) Uso de tinturas de cianina para el diagnostico de enfermedades asociadas con angiogenesis -p-sv-78.503/msu
SV2003001107A (es) Imidazotriazinas ref.lea 35368
CL2008000836A1 (es) Compuestos derivados de tiazolidina, antagonistas del receptor de orexina; composicion farmaceutica que los comprende; y su uso en el tratamiento de neurosis emocional, depresion grave, trastornos psicoticos, alzheimer, parkinson, dolor, entre otras.
ECSP045081A (es) Derivados de 1,8-naftiridina y su uso para el tratamiento de la diabetes y trastornos relacionados
DK1961418T3 (da) Anvendelse af isothiocyanatforbindelser til behandling af prostatasygdomme og hudcancer
CL2007001918A1 (es) Compuestos derivados heteroarilos sustituidos; metodo para la preparacion de los compuestos; composicion farmaceutica; y uso para el tratamiento del dolor, depresion, enfermedad de alzheimer e hipertension entre otras.
GT200500158A (es) Derivados de amino-5,5-difenilimidazolona para la inhibicion de la b-secretasa
BR0211905A (pt) Dialdeìdos de rapamicina
ECSP088905A (es) Nuevos compuestos
UY27943A1 (es) Composiciones y mctodos para tratar el crncer usando inmunoconjugados de anticuerpo para cd44 citotnxicos y agentes quimioterapcuticos
CL2008002139A1 (es) Compuestos dimeros derivados de pirrolo[2,1c][1.4]benzodiazepina- 5 -ona (tomaimicina), conjugado que los comprenden; procedimiento de preparacion de los conjugados; composicion farmaceutica que comprende a los compuestos o conjugados; y uso de los compuestos y de los conjugados en el tratamiento del cancer.
BRPI0519047A2 (pt) mÉtodo para a produÇço de um agente de contraste marcador ou agente terapÊutico marcador, agentes de contraste marcadores e uso de agentes de contraste marcadores ou de agentes terapÊuticos marcadores
ECSP088593A (es) 5-(arilsulfonil)-pirazolopiperidinas
ECSP088241A (es) Un conjugado citotóxico ca6 antígeno-específico y métodos para utilizar el mismo
DK1938839T3 (da) Oftalmiske sammensætninger af parasympatiske stimulanter og anti-inflammatoriske midler til anvendelse i behandlingen af presbyopi
SV1997000002A (es) 2-oxo y 2-tio-1,2-dihidroquinolinil-oxazolidinonas ref. lea 31477-sv
UY29149A1 (es) Tiazolil-dihidro-indazoles
BR0015992A (pt) Compostos, utilização dos mesmos, e, associações terapêuticas
GT200500098A (es) Nuevos compuestos
CR10165A (es) "uso de derivados de sulfamida heterociclo benzo-fusionado para el tratamiento de depresión"
BRPI0810647A2 (pt) " uso de trans carotenóides bipolares como um pré-tratamento e no tratamento de doença vascular periférica ".
ECSP055964A (es) Heterociclil-3-sulfonilindazoles como ligandos de 5-hidroxitriptamina-6
CL2008002808A1 (es) Compuestos derivados de benzoxazol, agonistas del receptor muscarinico m1; composicion farmaceutica que comprende a dichos compuestos; y uso para el tratamiento de esquizofrenia, alteraciones cognitivas o enfermedad de alzheimer.
DE602005020474D1 (de) Antikörper gegen Phosphorylcholinkonjugate
UA101961C2 (xx) Кристалічна форма 1 2-((r)-2-метилпіролідин-2-іл)-1h-бензімідазол-4-карбоксаміду$кристаллическая форма 1 2-((r)-2-метилпирролидин-2-ил)-1h-бензимидазол-4-карбоксамида

Legal Events

Date Code Title Description
FD Lapse